Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Bibliographic Details
Main Authors:	Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Junko Morii, Eriko Kunikane, Taiji Sakamoto
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-08-01
Series:	Ophthalmology and Therapy
Online Access:	https://doi.org/10.1007/s40123-023-00788-9

Similar Items

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
by: Yasuo Yanagi, et al.
Published: (2023-05-01)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
by: Apsangikar P, et al.
Published: (2021-07-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
by: Matthews Jane P, et al.
Published: (2008-06-01)

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
by: Chakravarthy, U, et al.
Published: (2012)

Ranibizumab port delivery system in neovascular age-related macular degeneration
by: Priya R. Chandrasekaran, et al.
Published: (2022-02-01)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
by: Chakraborty D, et al.
Published: (2023-04-01)

Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
by: Sivaprasad, S, et al.
Published: (2011)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
by: Andreas Maunz, PhD, et al.
Published: (2023-12-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
by: Yi-Sheng Chang, et al.
Published: (2018-05-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
by: Tryfon Rotsos, et al.
Published: (2010-11-01)

Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration
by: Ai Kuranami, et al.
Published: (2023-05-01)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
by: Scorcia G, et al.
Published: (2010-05-01)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
by: Russo A, et al.
Published: (2018-03-01)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
by: Cvetkova NP, et al.
Published: (2016-06-01)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration.
by: Rishma Gohil, et al.
Published: (2015-01-01)

One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients
by: Satoru Inoda, et al.
Published: (2024-01-01)

Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
by: Aditya S Kelkar, et al.
Published: (2021-01-01)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.
by: Yusuke Arai, et al.
Published: (2020-01-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
by: Pongsachareonnont P, et al.
Published: (2018-09-01)

Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey
by: Zafer Cebeci, et al.
Published: (2018-02-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

Role of ranibizumab in management of macular degeneration
by: Singh Rishi, et al.
Published: (2007-01-01)

Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab.
by: Pearce, E, et al.
Published: (2011)

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
by: Menke, Marcel N., et al.
Published: (2013)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)

Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration
by: Bekir Küçük, et al.
Published: (2018-04-01)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.
by: Frank G Holz, et al.
Published: (2020-01-01)

Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography – case report
by: Martin Pencak, et al.
Published: (2021-01-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”
by: Dan Călugăru, et al.
Published: (2018-11-01)

Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration
by: Jay Kumar Chhablani
Published: (2010-01-01)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
by: So Young Han, et al.
Published: (2015-02-01)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Ki Won Jin, et al.
Published: (2021-07-01)

Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab
by: Cemal Çavdarlı, et al.
Published: (2021-04-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)